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ABSTRACT
Alcohol Affects the Reward Pathway of the Brain via α6-Containing Nicotinic
Acetylcholine Receptors in the Nucleus Accumbens
Elizabeth Qiufeng Anderson
Neuroscience Center, Brigham Young University
Master of Science
The prevailing view is that enhancement of dopamine (DA) transmission in the mesolimbic
system consisting of DA neurons in the ventral tegmental area (VTA) that project to the nucleus
accumbens (NAc) underlies the rewarding properties of ethanol (EtOH) and nicotine (NIC).
Although the dogma is that EtOH enhancement of DA neural activity contributes to
enhancement of DA transmission, DA neurons are not sensitive to rewarding levels of EtOH.
However, VTA GABA neurons are sensitive to low-dose EtOH. We have shown previously that
EtOH modulation of DA release in the NAc is mediated by α6-containing nicotinic receptors
(α6*-nAChRs), that α6*-nAChRs mediate low-dose EtOH effects on VTA GABA neurons and
EtOH preference, and α6*-nAChRs may be a molecular target for low-dose EtOH. Thus, the
most sensitive target for reward-relevant EtOH modulation of mesolimbic DA transmission and
the involvement of α6*-nAChRs in the mesolimbic DA reward system remains to be elucidated.
The aim of this study was to evaluate EtOH effects on VTA GABAergic input to CINs and DA
release in the NAc. Using DIO channel rhodopsin-2 (ChR2) viral injections into the VTA of
VGAT Cre mice, we found that VTA GABA neurons send an inhibitory projection to CINs,
replicating what has been demonstrated by others. This study investigated the acute and chronic
effects of EtOH at this synapse. We demonstrate that EtOH markedly enhances CIN firing rate
and that these effects are blocked by the α6-conotoxin MII (α-Ctx MII), knockout of accumbal
α6*-nAChRs with α6-shRNA, and atypical GABA receptor antagonists. This study also
investigated plasticity at this synapse. We demonstrate that a low frequency stimulation (LFS; 1
Hz, 240 pulses) causes inhibitory long-term depression at this synapse (CIN-iLTD) which is also

blocked by α-Ctx MII, α6-shRNA, and atypical GABA receptor antagonists. We also show that
CIN-iLTD is blocked in EtOH-dependent mice. Taken together, these findings suggest that
EtOH affects the VTA GABAergic projection to CINs via α6*-nAChRs and that atypical GABA
receptors also play a role.

Keywords: alcohol, nicotine (NIC), cholinergic interneurons (CINs), nicotinic acetylcholine
receptors (nAChRs), alpha6 (α6)
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ALCOHOL AFFECTS THE REWARD PATHWAY OF THE BRAIN VIA α6CONTAINING NICOTINIC ACETYLCHOLINE RECEPTORS IN THE
NUCLEUS ACCUMBENS

Negative Impact of Alcohol Use Disorder and Tobacco Use Disorder
Alcohol drinking and tobacco smoking are leading causes of premature death and disease
in the United States, with both substances often co-abused. Approximately 80% of alcoholdependent individuals are tobacco smokers (Bobo & Husten, 2000; Matson & Grahame, 2015).
Nearly 17 million Americans have an alcohol use disorder (AUD), but only approximately 1.3
million adults receive (SAMHSA, 2016), leaving over 90% untreated. The estimated economic
costs of AUD to the US in 2015 was $249 billion, with almost three-quarters related to binge
drinking (Sacks, Gonzales, Bouchery, Tomedi, & Brewer, 2015; SAMHSA, 2016). The
estimated direct medical care costs associated with tobacco smoking in 2014 was $170 billion
(Report, 2014; Xu, Bishop, Kennedy, Simpson, & Pechacek, 2015). The economic, societal,
familial, and personal costs associated with AUD and tobacco smoking are staggering.
Elucidating how alcohol and tobacco affect the brain on a synaptic level is imperative to develop
robust, long-lasting treatment.

The Mesolimbic Dopamine System
The compulsion to consume EtOH and NIC stems from both their positive reinforcing
properties, including anxiolytic and euphoric effects, and negative reinforcing properties,
including aversive withdrawal symptoms that result from abstinence (Koob, 2003). Symptoms
of dependence accumulate with repeated drug taking and withdrawal (Overstreet, Knapp, &
Breese, 2002). A large body of research has supported the idea that the rewarding effects of
ethanol (EtOH), nicotine (NIC), and other psychoactive drugs are dependent on mesolimbic
1

dopamine (DA)-mediated neurotransmission (Blackburn, Phillips, Jakubovic, & Fibiger, 1986;
Koob, 1992; Wise, 1996; Wise, 2004; Wise & Bozarth, 1987). Current dogma maintains that DA
neuron activation and release in the mesolimbic DA system originating in the midbrain ventral
tegmental area (VTA) and projecting to the nucleus accumbens (NAc) of the ventral striatum is
literally a scalar index of reward (Wise, 2008). The emerging view is that the dysregulated
homeostasis that accompanies the development of drug addiction may result from experiencedependent neuroadaptations that hijack normal synaptic transmission in this system (Hyman &
Malenka, 2001; Hyman, Malenka, & Nestler, 2006; Kauer & Malenka, 2007; Nugent & Kauer,
2008).

Nicotinic Receptors in the Mesolimbic Dopamine System
Neurons within the VTA express a wide variety of nicotinic acetylcholine (ACh)
receptors (nAChRs) (Wooltorton, Pidoplichko, Broide, & Dani, 2003), with heteromeric α4β2and homomeric α7-nAChRs the most widely expressed subtypes in the mammalian brain. It has
long been established that NIC exerts its effects by binding to these pentameric ligand-gated
channels. Although NIC activates both DA and inhibitory γ-amino butyric acid (GABA) neurons
in the VTA (Mansvelder, Keath, & McGehee, 2002; Yin & French, 2000), the majority of
endogenous cholinergic (CIN) inputs into the VTA appear to contact GABA rather than DA
neurons (Fiorillo & Williams, 2000; Garzon, Vaughan, Uhl, Kuhar, & Pickel, 1999), suggesting
that NIC in the VTA primarily affects DA transmission indirectly by binding to nAChRs to first
affect GABA transmission. The majority of the GABA neurons in the VTA express α4 and β2
subunits (Mansvelder et al., 2002). Indeed, the emerging view is that the early, acute effects of
NIC in the VTA predominantly affect GABA neurons and that associated nAChRs desensitize
rapidly, leading to a long-lasting excitation of DA neurons through removal of the inhibitory
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influence of GABA. Since NIC is present in the brain of smokers about 10-20 sec after
absorption (Benowitz, 1988; Oldendorf, 1974) reaching blood concentrations of NIC in the range
of 250-500 nM during and after cigarette smoking (Henningfield, Stapleton, Benowitz, Grayson,
& London, 1993), it has been proposed that during NIC addiction, all nAChRs become
desensitized by NIC since NIC is present in the brain of smokers about 10-20 sec after
absorption (Benowitz, 1988; Oldendorf, 1974). It has also been proposed that after prolonged
exposure to NIC, a shift occurs in the activity level of DA neurons relative to GABA cells in the
VTA, ultimately favoring increased activity of the mesolimbic DA pathway (Mansvelder et al.,
2002).

Common Neuronal Substrates Underlying Alcohol and Nicotine Reward and Dependence
Some progress has been made over the past 4 decades to define sites of alcohol actions on
several pentameric ligand-gated ion channels, including GABA(A)Rs, glycine receptors, and
nAChRs (Trudell, Messing, Mayfield, & Harris, 2014). However, unlike other addictive drugs
(e.g., morphine, cocaine, and nicotine) that have specific molecular targets on neurons, there is
no clear molecular target for EtOH that has been validated or accepted by the alcohol research
community. Thus, it is highly important to identify and characterize new targets that are sensitive
to low-dose EtOH and how they affect reward signaling as lower doses of EtOH are considered
rewarding.
Accumulating evidence suggests nAChRs serve as common substrates that regulate the
motivational properties of both NIC and EtOH. NIC, for example, stimulates EtOH drinking in
both humans and rodents (Britt & Bonci, 2013; Doyon, Dong, et al., 2013; Doyon, Thomas,
Ostroumov, Dong, & Dani, 2013; Le, Wang, Harding, Juzytsch, & Shaham, 2003; Ostroumov,
Thomas, Dani, & Doyon, 2015; Smith, Horan, Gaskin, & Amit, 1999). Conversely, the nAChR
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partial agonist varenicline, marketed as the smoking cessation agent Chantix, decreases EtOH
intake in alcohol-dependent humans (Mitchell, Teague, Kayser, Bartlett, & Fields, 2012; Reus et
al., 2007; Rollema et al., 2007) and rodents (Blomqvist, Ericson, Johnson, Engel, & Soderpalm,
1996; Steensland, Simms, Holgate, Richards, & Bartlett, 2007).On a molecular level, EtOH has
been documented to play a direct role in the allosteric modulation, stabilization, desensitization,
and internalization of nAChRs as well as the up- and down-regulation of these functions (Dopico
& Lovinger, 2009).
In particular, heteromeric α6*-nAChRs (α6*-nAChRs; * denotes α6 subunits combined
with other nAChR subunits) have been proposed at a substrate for EtOH. Administration of αconotoxin MII (α-Ctx MII), a potent antagonist of α6*-nAChRs, locally into the VTA reduces
EtOH-induced NAc DA release (Larsson, Jerlhag, Svensson, Soderpalm, & Engel, 2004),
reduces EtOH-induced locomotor activity (Jerlhag, Grotli, Luthman, Svensson, & Engel, 2006),
blocks recognition of EtOH-associated cues (Lof et al., 2007), and blocks voluntary EtOH
drinking in rodents (Larsson et al., 2004). Likewise, over-expressing α6*-nAChRs (α6L9'S
subunits) alters EtOH-induced behaviors (Powers, Broderick, Drenan, & Chester, 2013; Y. Wang
et al., 2014). Although α4β2- and α7-nAChRs are the most widely expressed neuronal subtypes
in the mammalian brain and the majority of the GABA neurons in the VTA express α4 and β2
subunits as noted previously, there is considerable expression of heteromeric α6*-nAChRs in the
VTA. In fact, α6*-nAChR subunit mRNA levels are 16-fold higher than other nAChR subunits
in the VTA (Yang, Jin, & Wu, 2009), suggesting α6*-nAChRs are major molecular regulators of
addiction.

4

Theoretical Model

Figure 1: Theoretical framework.
(A) Under naive conditions, DA release in the NAc is controlled by local circuit VTA GABA
neurons and by CINs in the NAc. α6*-nAChRs are located at both GABAergic terminals on VTA
GABA neurons (putative) and DAergic terminals on MSNs. Current dogma maintains that D1MSNs project back to the VTA in a reciprocal inhibitory loop via the direct pathway. Based on
accumulated evidence, VTA GABA neurons play a critical role in inhibiting DA neurons and
CINs via local circuit GABA release in the VTA and projections to CINs. (B) Under acute
conditions, NIC or EtOH activates α6*-nAChRs on GABAergic terminals on VTA GABA
neurons and DA terminals in the NAc resulting in enhanced DA neuron activity and release
(darker shading of neurons and thickness of axons indicates more excitability). (C) Under chronic
NIC or EtOH conditions, α6-nAChRs are deeply desensitized, which reduces GABA release onto
VTA GABA neurons, thereby markedly enhancing GABA neuronal activity, which results in
enhanced inhibition of DA neurons and lowered DA release.

This project investigated the roles of the This project investigated the roles of the
GABAergic projections to accumbal CINs and α6*-nAChRs within the mesolimbic DA reward
system in mediating the effects of acute and chronic EtOH. The circuit involved is the
mesolimbic DA system, the cellular substrate is CINs, and the molecular focus is α6*-nAChRs.
The theoretical framework for the proposal (Fig. 1) is based on the synaptic hodology of VTA
GABA neuron projections to CINs and previously identified α6*-nAChRs.
Electrophysiological studies both in vivo and in vitro indicate that acute NIC (Erhardt,
Schwieler, & Engberg, 2002; Imperato & Di Chiara, 1986; Mansvelder et al., 2002; Yin &
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French, 2000) and EtOH (Brodie & Appel, 1998; Brodie, Shefner, & Dunwiddie, 1990; Gessa,
Muntoni, Collu, Vargiu, & Mereu, 1985), like most drugs of abuse, increase VTA DA neuron
firing rate (EC50 of 120 mM EtOH in slice) and basal DA release in limbic structures. In
contrast, withdrawal from chronic EtOH reduces DA firing rate and release in the NAc (Diana,
Pistis, Carboni, Gessa, & Rossetti, 1993). Although the release of DA in the NAc positively
reinforces drug use, DA neurons are relatively insensitive to the direct effects of EtOH. Thus, it
has become increasingly evident that EtOH’s effects are not mediated directly on DA neurons or
release, but are mediated indirectly via actions on local VTA GABA neurons (Bocklisch et al.,
2013; Nugent & Kauer, 2008; Steffensen et al., 2011; Ting & van der Kooy, 2012) which are one
order of magnitude more sensitive than EtOH effects on DA neurons (Brodie & Appel, 1998;
Gysling & Wang, 1983; Mereu, K-W., Gessa, Naes, & Westfall, 1987). Indeed, optogenetic
studies demonstrate that selective activation of VTA GABA neurons inhibits DA neurons to
disrupt reward consumption (van Zessen, Phillips, Budygin, & Stuber, 2012) and drive
conditioned place aversion (Tan et al., 2012). These studies provide compelling evidence of the
importance of VTA GABA neurons in regulating DA transmission in the reward pathway.
Some discrepancies about drug effects on VTA GABA neurons exist. For example, our
lab and others have shown that NIC excites (Erhardt et al., 2002; Mansvelder et al., 2002; Yin &
French, 2000) while EtOH inhibits VTA GABA neuron activity (Stobbs et al., 2004), yet both
NIC and EtOH enhance DA neural activity and tonic DA release in limbic structures. The VTA
GABAergic projection to accumbal CINs, which has been shown to enhance associative learning
in one optogenetic study (Brown et al., 2012), helps explain such discrepancy and similar
discrepancies. For this project, we proposed and performed experiments focusing on this VTA
GABAergic projection to accumbal CINs.
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We also we proposed and performed experiments investigating plasticity at this synapse.
During withdrawal from EtOH, tolerance accrues to EtOH inhibition of VTA GABA neuron
firing rate and VTA GABA neurons recorded in vivo become hyperexcitable (firing rates
averaging >100 Hz) (Gallegos, Lee, Criado, Henriksen, & Steffensen, 1999). Thus, VTA GABA
neurons undergo pronounced adaptation during withdrawal from chronic EtOH. We have shown
in multiple reports that GABA(A) receptors [GABA(A)Rs] switch their function during opiate
dependence (Laviolette, Gallegos, Henriksen, & van der Kooy, 2004; Ting & van der Kooy,
2012; Vargas-Perez et al., 2014; Vargas-Perez et al., 2009), and recently, EtOH dependence
(Nelson et al., 2018).
As mentioned, it is suggested that α6*-nAChRs are major molecular regulators of
addiction. We have recently shown that α6*-nAChRs are expressed on GABA terminals
projecting to VTA GABA neurons and mediate low-dose EtOH effects (Steffensen et al., 2017).
Thus, this project also focused on experiments involving α6*-nAChRs in the NAc to dissect the
most sensitive substrate of EtOH.

Rationale and Core Hypothesis
We have previously demonstrated:
•

High-dose EtOH inhibits evoked DA release in the NAc via α6*-nAChRs
(Schilaty et al., 2014)

•

VTA GABA neurons express α6*-nAChRs (Steffensen et al., 2017)

•

Functional α6*-nAChRs can be expressed in cell lines (Chen et al., 2018)

•

α6*-nAChRs are a highly sensitive target for low-dose EtOH on GABAARmediated inhibition to VTA GABA neurons (Gao et al., 2019)

7

•

α6*-nAChRs mediate EtOH reward

(Steffensen et al., 2017)
However, the specific location in the brain
where α6*-nAChRs mediate EtOH effects
on DA release in the mesolimbic system
and EtOH reward cannot be determined
from these studies. This requires selective
activation and inactivation of the specific
pathway in the brain that expresses α6*nAChRs, which was the main objective of
this project. Given that some VTA GABA
neurons express α6*-nAChRs (Steffensen
Figure 2: Effects of low-dose EtOH on CINmediated spontaneous DA release in the NAc
core: Role of α6-nAChRs.
(A) Representative 1 min recordings of DA
transients under control (top) and 5 mM EtOH
(bottom) conditions. (B) The inset shows a
cyclic voltammogram taken at the time indicated
by the arrow. (C) EtOH significantly enhanced
the frequency of DA transients at the 5 mM
concentration.
(D) α-Ctx MII (100 nM)
prevented EtOH (5 mM) enhancement of DA
transient frequency. (E) EtOH also significantly
enhanced the amplitude of DA transients at the 5
mM level. (F) MII significantly reduced EtOH
(5 mM) enhancement of DA transient amplitude.
There was also a significant difference between
MII alone and MII+EtOH.

et al., 2017), and our published evidence
demonstrating that α6*-nAChRs mediate
EtOH enhancement of CIN-mediated DA
release (Fig. 2), the core hypothesis of this
proposal was that α6*-nAChR-containing
VTA GABA neuron input to CINs in the
NAc mediates EtOH effects on DA release,
EtOH reward, and adaptions to EtOH
dependence. At the prospectus, I proposed
a molecular, physiological, and circuit-

based approach to test the hypotheses as outlined below.

8

Specific Aims and Hypotheses
My thesis was organized around three Specific Aims and their accompanying hypotheses.
All Aims involved experiments related to the role of α6*-nAChRs in NIC and low-dose EtOH
effects on CINs. Aim 1 involved the elucidation of the VTA GABA neuron pathway to CINs and
the evaluation of the effects of low-dose EtOH and NIC on CIN excitability and DA release.
Aim 2 involved examination of low-dose EtOH and NIC on VTA-NAc GABAergic synaptic
modulation of CINs. Aim 3 involved determination of plasticity in the VTA-NAc GABAergic
pathway during EtOH dependence. Using a colony of VGAT-Cre transgenic mice crossed with
GAD67-GFP mice to facilitate visualization of neurons and specific activation of VTA GABA
neuron input to CINs, we were able to dissect the role of α6*-nAChRs in this pathway in
mediating NIC and EtOH effects on NAc CINs. The dissection was accomplished with selective
activation of the VTA-NAc GABAergic pathway via optogenetic stimulation of VTA GABA
neuron projections to CINs via ChR2 expression in VTA GABA neurons, as well as selective
inactivation of this pathway with viral interference technologies to dissect the role of α6*nAChRs. We evaluated the role of α6*-nAChRs in EtOH and NIC effects on CIN firing rate and
DA release (Aim 1), VTA GABAergic modulation of CINs and DA release (Aim 2); and VTA
GABAergic plasticity to CINs (Aim 3). All methods described within the Aims were operational
in Dr. Steffensen’s and Dr. Yorgason’s laboratories and described in each of the experiments, or
in detail in previous cited publications. Our collaborator, Dr. Michael McIntosh, at the
University of Utah has developed α-conotoxins (α-Ctxs) that are potent and specific for α6*nAChRs, perhaps arguably some of the most potent and specific pharmacological tools available
to neuroscience. VGAT-Cre mice and viral constructs enabled selective activation of VTA-NAc
GABAergic inputs to NAc CINs. Our collaborator, Dr. Anna Lee, has developed a Cre
recombinase-dependent RNA interference (shRNA) construct that targets α6*-nAChR subunits
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(α6-shRNA). Interference approaches were used to specifically knockdown α6*-nAChR
expression in VTA-NAc GABAergic inputs. We used a novel combination of optogenetic
modulation of VTA-NAc GABAergic inputs to VTA GABA neurons and knockdown
approaches with mouse models of EtOH dependence. The original hypotheses associated with
each Aim were:

•

Aim 1: We will evaluate the role of α6*-nAChRs in mediating EtOH effects on VTA
GABAergic synaptic transmission to CINs in the NAc
Hypothesis: α6*-nAChRs will mediate EtOH effects on VTA GABAergic synaptic
inhibition of CINs.

•

Aim 2: We will evaluate the role of α6*-nAChRs in mediating EtOH effects on CIN
activity and DA release in the NAc.
Hypothesis: α6*-nAChRs will mediate low-dose EtOH effects on CIN activity.

•

Aim 3: We will evaluate plasticity in the VTA GABAergic pathway to CINs, the role of
α6*-nAChRs, and changes in plasticity in EtOH-dependent mice.
Hypothesis: Long-term depression (LTD) of GABAergic input to CINs will switch to
long-term potentiation (LTP) in EtOH-dependent mice.

10

METHODS
Animal Subjects
VGAT-Cre mice were crossed with GAD67-GFP mice (VGAT-Cre/GAD67-GFP) which
enabled visualization and electrophysiology of VTA and NAc neurons. ChAT-ChR2-eYFP mice
were also used which enabled visualization and electrophysiology of CINs in the NAc. Only
male mice were used for this project. For each methodology to be employed, animals were
treated in strict accordance with the Brigham Young University (BYU) Animal Research
Committee (IACUC) guidelines, which incorporate and exceed current NIH guidelines. The
BYU IACUC reviewed and approved the procedures detailed herein. Once weaned at PND 21,
all mice were housed in maximum groups of five and given ad libitum access to solid food and
water and placed on a reverse light/dark cycle with lights ON from 8 PM to 8 AM.
AAV-DIO-ChR2-mCherry: AAV-DIO-ChR2-mCherry (DIO-ChR2) is one of many Cre
viral contrstructs that has been developed to transport retrogradely to a targeted brain region and
genetically manipulate the activity of defined neuronal subpopulations to elucidate function and
alter behavior (Gompf, Budygin, Fuller, & Bass, 2015). VGAT-Cre/GAD67-GFP mice were
injected bilaterally into the VTA with DIO-ChR2 (VGAT DIO-ChR2) to target VTA GABA
neurons projecting to the NAc and allow the generation of optically-evoked inhibitory
postsynaptic currents (oIPSCs) specifically from VTA GABA neurons (Fig. 3A). For the
procedure, mice were anesthetized with 2-4% isofluorane and injected bilaterally into the VTA
(A/P, -3.0; M/L, +0.5; D/V, -4.5 mm from bregma) under aseptic conditions with DIO-ChR2
(0.5-1 μL) using a needle made from a fire polished glass capillary. A microinjection pump
(World Precision Instruments, Sarasota, FL) was used to deliver the virus into each hemisphere
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Figure 3: Experimental framework for determination of GABAergic pathways from the VTA to
NAc CINs that express α6*-nAChRs and viral strategies to knockdown α6*-nAChRs.
(A) Activation of GABAergic inputs to NAc CINs from the VTA were obtained in brain slices
with blue light stimulation through the objective in VGAT-Cre/GAD67-GFP mice injected
with AAV-DIO-ChR2-mCherry into the VTA. (B) Knockdown (KD) of α6*-nAChRs in the
NAc was accomplished in the VTA-NAc pathway in the same mice with injections of AAVflex-mRuby2-α6shRNA into the VTA. (C) Optical activation of CIN-mediated DA release was
accomplished in ChAT-ChR2-eYFP mice.
at a rate of 0.075uL/min. Mice were sutured and housed in a single cage until full recovery (~7
days) and the virus incubated for 3-4 weeks to reach peak expression in the NAc before
experimentation.
AAV-flex-mRuby2-α6shRNA: Our hypothesis is that GABA terminals on VTA GABA
neurons projecting to CINs in the NAc express α6*-nAChRs. Co-I Lee developed a Cre
recombinase-dependent RNA interface (shRNA) construct that travels anterogradely and targets
α6*- nAChR subunits (Fig. 3B). To dissect α6*- nAChR-relevant VTA GABA neuron outputs to
CINs, VGAT-Cre/GAD67-GFP mice were injected bilaterally into the VTA with AAV-flexmRuby2-α6shRNA (α6*- shRNA) and control (0.5-1 μL). The virus incubated for 3-4 weeks to
reach peak expression in the NAc before experimentation. Finally, to activate CINs directly we
used a ChAT-ChR2-eYFP mouse and stimulated the neurons optically with blue light.
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Chronic Intermittent Ethanol Exposure

Figure 4: Diagrammatic representation of the vapor chamber apparatus used in CIE
administration
Chronic Intermittent Ethanol Exposure (CIE) was used to model EtOH-dependence and
withdrawal. The Steffensen lab has published many papers on this paradigm: two recent papers
describing the use of EtOH vapor chambers mice to produce dependence (Nelson et al., 2018;
Williams et al., 2018). VGAT-Cre/GAD67-GFP mice were placed in EtOH vapor chambers
combined with EtOH drinking to establish EtOH dependence and air vapor chambers combined
with water as a control. We modified the vapor chamber system developed in the lab of Graeme
Mason at Yale (J. Wang, Jiang, Du, & Mason, 2012). The six automated chamber system (Fig.
4) consisted of an air-pressurized, feedback-controlled EtOH flask with flow valves to each of
three sealed chambers to regulate the flow of air (11 L/min) and concentration of EtOH to three
of six chambers placed in a ventilation hood. A breathalyzer (Drager Alcotest 6510) was used in
a feedback loop to regulate the concentration of EtOH. In order to avoid overdosing the first
week of CIE vapor exposure, mice were exposed to 4, 6, and 8 h of vapor before exposing to 16
13

h vapor/day in order to induce tolerance. Control animals were housed in three sealed chambers
in the same ventilation hood, but only received air. Alcohol levels were controlled with a
modified feedback system using a breathalyzer. Blood alcohol levels (BALs) were measured
using an enzymatic kit (Sigma-Aldrich, St. Louis, MO). Even at the 5 L/min feedback flowmeter
level the air-exposed mice did not show any detectable alcohol above the 1 mg% detection limit
of the breathalyzer or the BAL determination method.

Immunohistochemistry
Animals were anesthetized in 2-4% isoflurane then underwent transcardial perfusion with
4% paraformaldehyde (PFA). Once perfused, brains were carefully removed and placed in 4%
PFA for at least 24 hrs to facilitate continued fixation. After incubation in PFA, brains were
placed in a solution of 30% sucrose in phosphate buffered saline (PBS) until the density of the
brain matched that of the solution and the brains dropped to the bottom of the vial (~24-48 hrs).
Brains were then flash frozen in dry ice and mounted on a cold microtome stage. Targeting the
VTA and NAc, brains were sliced at 40 μm and slices were placed in cryoprotectant (30%
ethylene glycol, 30% sucrose, 0.00002% sodium azide, in 0.1 M PBS) and kept at -20°C until
mounting. To mount slides, sections were placed on microscope slides and dried for ~5 min.
Once dried, a drop of vectashield (Vector Laboratories) was placed on the tissue, and a coverslip
was placed on the slide. Slides were allowed to set overnight, and then were kept at 4°C until
imaging. An Olympus FluoView FV1000 confocal microscope was used to image mounted
slices. Brain slices were mounted on microscope slides and imaged under oil immersion at 60X.
To ensure consistent readings between samples, a constant photomultiplier tube voltage and gain
were set between all acquired images.
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Patch-clamp Recordings
All brain slice preparations were performed in P18-120 day old ChAT ChR2 eYFP or
VGAT-Cre/GAD67-GFP mice in order to visualize ChAT+ or GAD67+ neurons in the NAc by
GFP and mCherry fluorescent imaging. Brains were extracted via anesthetization with 2-4%
isoflurane. Upon extraction, the brain was glued onto a cutting stage. The brain was then
sectioned in room temperature (ACSF; in mM: 124 NaCl, 3 KCl, 1.25 NaH2PO4, 26 NaHCO3, 12
glucose, 1.5 MgSO4, 2 CaCl2) and bubbled with 95% O2 / 5% CO2. Targeting the NAc, coronal
slices (210 μM thick) were placed in an incubation chamber containing ACSF perfused with
95% O2 / 5% CO2 for at least 30 min. After 30 min, brain slices were then placed in a recording
tissue chamber with ACSF continuously flowing at physiological temperatures (35 °C).
Fluorescent cells were imaged on a Nikon Eclipse FNI microscope with a 40x/0.80 n.a. objective
lens. The filter cube for GFP detection was a Nikon C-FL ENDOW GFP 96343 cube (Bandpass:
450-490 nm; Barrier: 500-550 nm; dichroic: 495 nm). Excitation was performed with a Sutter
Lambda TLED transmitted light source at 506 nm. Cells were then imaged using differential
interference contrast imaging in order to facilitate cell attached recordings. Ethanol was only
administered in animals older than day P28. All mice used in ethanol exposure groups were agematched and were P28-120 days old with a median age at day P55.
Miniature inhibitory postsynaptic currents (mIPSCs) were recorded in the presence of
lidocaine and kynurenic acid. Electrodes with a resistance of 3–5 MΩ between the pipette and
external solutions were used to form tight seals (>1 GΩ) on the cell surface, until suction was
applied in order to convert to conventional whole-cell recording. A holding potential (VH) of −70
mV was used and ionic currents measured in response to drug application. IPSCs were evoked in
VGAT-Cre/GAD67-GFP mice by 4 msec pulses of blue light (480 nm) following injection of
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DIO-ChR2-mCherry into the VTA and recorded in the presence of 1.4 mM kynurenic acid to
block glutamate-mediated synaptic currents.
While most striatal neurons are not autonomously active, CINs exhibit a regular spiking
activity in absence of any synaptic inputs (Bennett, Callaway, & Wilson, 2000). Cell-attached
patch-clamp techniques were used to record CIN firing rate. Electrodes with a resistance of 3–5
MΩ between the pipette and external solutions were used to form tight seals (10 MΩ–1 GΩ) on
the cell surface. Positive pressure was applied to the electrode when approaching the neuron. By
applying suction to the electrode, a seal (10 MΩ – 1 GΩ) was created between the cell
membrane and the recording pipette. Spontaneous spike activity was then recorded in cellattached mode with an Axon Instruments Multiclamp 700B amplifier, sampled at 10 kHz using
NIDAW boards, and collected and analyzed using Axograph software. Neurons were not
clamped throughout these experiments although recorded in voltage-clamp mode (voltage-clamp
was set to 0 mV). Firing rate recordings in this study were performed in cell-attached mode in
order to avoid dialyzing the contents of the cells and disrupting the cytoplasmic milieu (e.g., the
Cl− ion gradient), which we have shown previously is perturbed with drug dependence (Ting &
van der Kooy, 2012; Vargas-Perez et al., 2014). A stable baseline recording of firing activity was
obtained for 5–10 min before adding drugs. Neurons that did not achieve a stable baseline firing
rate during this time were rejected from the study.

Characterization of CINs
VTA GABA neuron inhibition of CINs was the pathway focus for most of the
electrophysiological recordings from this experiment performed on accumbal CINs. In ChATChR2-eYFP mice, CINs could be visualized as YFP+ mice. In non-ChAT mice, CINs in the
NAc were characterized by their large size, shape, and the presence of an Ih current for whole-
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cell patch-clamp experiments. In the VGAT-Cre/GAD67-GFP mice, CINs were also visualized
in the slice preparation as non-GFP neurons amongst predominantly GABA neurons in the
striatum.

Drug Preparation and Administration
200 Proof EtOH (Decon Labs, King of Prussia, PA, USA) was added directly to ACSF to
the desired concentrations (5 mM, 10 mM, 20 mM, 40 mM, 60 mM, 80 mM). All other drugs
used in vitro were made fresh from powder in distilled water, then added to ACSF and
superfused onto brain slices: Nicotine tartrate (Sigma‐Aldrich, St. Louis, MO, USA), TPMPA
(Tocris Bioscience, Bristol, UK), α-Ctx MII [H9A; L15A] (gift from Co-I McIntosh, University
of Utah, Salt Lake City, UT, USA).

Statistical Analyses of Responses
IPSCs were recorded every 20 sec and averaged into 1 min bins in Excel (Microsoft). The
last 5 min of 1 min averages before treatment (i.e., drugs or LFS) were again averaged and all
other values of the time course of effect were normalized to this average. Comparisons were
made between 5 min of values before treatment and 5 min after drug treatment or 30-35 min
after LFS. Firing rate was determined from windowed and discriminated spike times and
histogrammed into 10 sec bins. Averaged firing rate of 5 min was determined on ratemeters by
rectangular integration in Igor Pro (Wavemetrics, Oswego, OR). The last 5 min of integrated
firing rate before treatment (i.e., drugs) was compared against 5 min of drug effects 5 min after
administration unless otherwise indicated. All results were presented as raw mean values and
percent control ± SEM. Results between groups were compared using a two-tailed unpaired t test
or ANOVA. Experiments relying on variance in time or current were analyzed using mixed
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models ANOVA with post hoc t-test at individual points. Statistical significance required ≥ 95%
level of confidence (P≤0.05). Analysis software included Microsoft Excel and Igor Pro
(Wavemetrics, Oswego, OR). Significance levels are indicated on graphs with asterisks *,**,***
and correspond to levels P<0.05, 0.01 and 0.001, respectively. Figures were constructed with
Igor Pro software.

18

RESULTS
VTA GABA Projection to Accumbal CINs

Figure 5: Identification of NAc CINs and GABA Innervation.
(A) In C57Bl6 mice, GABA Rho-1 subunits (red) were expressed in cholinergic neurons
(green) in the NAc core. (B) In GAD67 GFP mice, Rho-1 subunits were not expressed in GFP+
MSN GABAergic neurons in the NAc core. (C) CINs in ChAT-YFP mice. (D) 60X image of
NAc neurons following injection of a6-shRNA mRuby into the VTA of VGAT-Cre/GAD67GFP mice. Note the punctate mRuby labeling on non-GFP+ neurons that are presumed to be
CINs. GFP+ neurons are MSNs and do not exhibit mRuby punctate labeling. (E) Magnified
view of the box in D. Arrows in A-C show neuron that is magnified in window. AC = anterior
commissure. Calibration bar indicates 50 μm.
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Based on previous studies, we determined that EtOH effects on evoked (Schilaty et al.,
2014) and spontaneous (Steffensen et al., 2017) DA release in the NAc was mediated by α6*nAChRs. The dogma is that α6*-nAChRs are on DA terminals. However, their role in mediating
Ach release from CIN terminals is not known. Given that VTA GABA neurons project to CINs,
we sought to determine the synaptic hodology of GABA inputs to CINs and the locus of α6*nAChRs. Using immunohistochemistry in C57Bl6, GAD67-GFP and ChAT YFP mice, we were
able to identify CINs and the expression of atypical GABAARs, mainly Rho-1 receptors (Fig.
5A-C). In addition, we confirmed the elegant work of the Luscher lab demonstrating that VTA
GABA neurons project to the NAc (Brown et al., 2012) by injecting a6-shRNA Cre mRuby into
the VTA of VGAT-Cre/GAD67-GFP mice and probing for mRuby puncta in the NAc (Fig.
5D,E). Although somewhat preliminary (need to stain for CINs with ChAT), putative CINs in
the NAc are innervated by VTA GABA neurons, as mRuby would be expressed only in VTA
GABA neurons that project to the NAc in VGAT-Cre mice.

EtOH Reduces GABAergic Transmission to CINs via Atypical GABA Receptors
In Aim 1, I hypothesized that α6*-nAChRs would mediate low-dose EtOH effects on
CIN activity and that VTA GABA projections to accumbal CINs form a critical nexus for EtOH
effects. We first evaluated the effects of EtOH (5-80 mM) on GABA synaptic transmission to
CINs by studying both spontaneous and evoked GABAergic responses (Fig. 6). A number of
recent optogenetic studies have demonstrated that selective activation of VTA GABA neurons
inhibits DA neurons and drives conditioned place aversion (Tan et al., 2012), disrupts reward
consumption (van Zessen et al., 2012), and that their projections to the NAc inhibits cholinergic
interneurons (CINs) to enhance associative learning (Brown et al., 2012), providing compelling
evidence for the importance of GABA neurons in regulating DA transmission in the reward
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pathway. In order to specifically evaluate the role of VTA GABA projections to NAc CINs, we
injected DIO-ChR2-mCherry into the VTA of VGAT-Cre/GAD67-GFP mice, which allowed for
the elicitation of oIPSCs specifically from VTA GABA neurons projecting to CINs. CINs were
characterized by a prominent Ih current in these mice, as they did not allow for the visualization
of CINs as in ChAT mice. oIPSCs were recorded from CINs in the NAc, confirming VTA
GABA projections to accumbal CINs. We found that EtOH (5-80 mM) significantly decreased
oIPSCs in CINs in VGAT-Cre/GAD67-GFP mice (Fig. 6A-C) as well as (Fig. 6D). This was
most surprising given that EtOH typically enhances GABAergic synaptic transmission (e.g.,
IPSCs) in most systems (Siggins, Roberto, & Nie, 2005; Weiner & Valenzuela, 2006). These
oIPSCs were not sensitive to the typical GABA(A)R antagonist bicuculline (Fig. 6E). The Rho-

Figure 6: EtOH reduced GABAergic transmission to CINs.
(A,B) Ethanol (5-80 mM) significantly decreased CIN mIPSC and sIPSC frequency. (C) CINs
are characterized by Ih current (top; -60 to 120 mV step). Representative traces showing that
optical stimulation (blue light; 4 msec) in VGAT-ChR2 mice induces IPSCs (oIPSCs) and
EtOH (5 mM) decreases oIPSCs in this CIN (bottom). (D) Ethanol (5-80 mM) significantly
decreases oIPSCs in CINs in VGAT-ChR2 mice. (E,F) Representative traces showing that
optical stimulation in VGAT-Cre mice injected with DIO ChR2 into the VTA is reduced by 5
mM EtOH.
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1 antagonist (1,2,5,6-Tetrahydropyridine-4-yl) methylphosphinic acid (TPMPA; 10 μM) was the
only drug that blocked EtOH inhibition of mIPSCs (Fig. 6A). The inhibition of CIN GABAergic
responses is not totally unexpected, as GABAergic responses in Rho-1 receptors expressed in
Xenopus oocytes have been shown to be inhibited by physiologically-relevant doses of EtOH
(Mihic & Harris, 1996). Thus, there are clear differences between EtOH effects in the VTA
versus the NAc that merit elucidation.

EtOH Enhances CIN Firing Rate via α6*-nAChRs
In Aim 2, I hypothesized that α6*-nAChRs would mediate low-dose EtOH effects on
CIN activity. As CIN oIPSCs were inhibited by EtOH, we conjectured that the reduction of
GABAergic inhibition to CINs would result in enhanced firing rate. Thus, we evaluated the
effects of EtOH on CIN firing rate (Fig. 7). CINs are inhibited by muscarinic receptor agonists
like muscarine due to autoreceptor inhibition, which is a pharmacological way to distinguish
them from other neurons in the NAc (Fig. 7A). The baseline firing rate of CINs in the slice
preparation was 0.47 ± 0.08 Hz. It was not affected by superfusion of α-Ctx MII (p>0.05), but
was significantly increased by injection of a6-shRNA into the VTA (Fig. 7E; F(1,19) = 40.7,
p<5.3E-06; n=10,11). Consistent with EtOH inhibition of CIN IPSCs, CIN firing rate was
markedly enhanced by increasing concentrations of EtOH (5-80 mM) in VGAT-Cre mice (Fig.
7B; F(5,90) = 26.3, p<1.7E-06), which was blocked by α-Ctx MII and injection of a6-shRNA into
the VTA (Fig. 7C,D,F), suggesting that α6*-nAChRs are involved.
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Figure 7: EtOH markedly enhances CIN firing rate with block by α6*-Ctxs or depletion of α6*nAChRs.
(A) CINs visualized in ChAT mice are characterized by auto-receptor inhibition by the M2
agonist muscarine. Insets are 5 sec representative spike recordings before (a), during (b), after
(c) muscarine (wash). Times for (a,b,c) are indicated on the representative ratemeter below. (B)
In putative CINs inhibited by muscarine in VGAT-Cre mice, firing rate is enhanced by
increasing doses of EtOH. Insets are 5 sec spike recordings before (a), during 20 mM EtOH
(b), and during 40 mM EtOH at the times indicated on the representative ratemeter below. (C)
Block of EtOH enhancement of CIN firing rate at high doses by the α-Ctx MII. (D)
Enhancement of CIN baseline firing rate and block of EtOH enhancement of CIN firing rate in
mice injected with AAV-flex-mRuby2-α6shRNA into the VTA. Inset (a) is during 5 mM EtOH
showing the enhancement at low doses of EtOH. (E) Summary of effects of α6-shRNA or MII
on CIN baseline firing rate. (F) Summary of EtOH effects in mice treated with MII or α6shRNA.
Consistent with what we observed with oIPSCs (Fig. 6), EtOH enhancement of CIN
firing rate was also blocked by TPMPA (10 μM; Fig. 8), suggesting that EtOH exerts its effects
on CINs in the NAc by reducing GABAergic transmission from the VTA through the atypical
GABA receptors like Rho-1. Finally, CIE exposure significantly increased the baseline firing
rate of CINs 147 % vs air exposed mice (F(1,16) = 10.2, p=0.006; n=10,8) and induced tolerance
to EtOH enhancement of CIN firing rate, suggesting neuroadaptations in this pathway (Fig. 9).
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Effects of EtOH on CIN-mediated DA Release
In Aim 2, I also hypothesized that α6*-nAChRs
would mediate CIN-mediated DA release. Striatal DA
release can be independently triggered not only by
release from DA terminals by DA neuron action
potentials but also by CIN action potentials. Electrical
stimulation would activate both of these DA release
mechanisms. However, using selective activation of
CINs with optical stimulation in ChAT-ChR2 mice it
Figure 8: Role of GABA Rho-1
receptors in EtOH enhancement of
CIN firing rate.
(A) This ratemeter shows a
representative ratemeter recording of
a CIN following TPMPA (10 µM)
and EtOH. (B) TPMPA blocked
EtOH enhancement of CIN firing
rate.

has been shown that CIN-mediated DA release, but not
DA terminal
evoked DA
release in the
dorsal
striatum, is

suppressed by low-dose NIC (IC50=28 nM) which may
explain why we and others have demonstrated that NIC
and EtOH paradoxically reduce electrically-evoked DA
release at terminals in the NAc. We have shown
previously that EtOH inhibition of evoked DA release
in the NAc is blocked by α-Ctx MII and mediated by
α6*-nAChRs (Y. Wang et al., 2014). Accordingly, we
show evidence demonstrating that CIN-mediated DA
release in ChAT-ChR2 mice is markedly reduced by

24

Figure 9: Tolerance to EtOH
enhancement of CIN firing rate in
dependent mice.
(A) This ratemeter shows a
representative ratemeter recording
of a CIN in a mouse during
withdrawal from CIE. (B) Chronic
ethanol
exposure
produced
tolerance to EtOH enhancement of
CIN firing rate.

EtOH (40 mM; Fig. 10). We still need to determine if it is mediated by α6*-nAChRs and
blocked by α-Ctx MII.

α6*-nAChRs Mediate CIN-iLTD
In Aim 3, I hypothesized that long-term depression
(LTD) of GABAergic input to CINs will switch to long-term
potentiation (LTP) in EtOH-dependent mice. The
enhancement in baseline firing rate with α6- shRNA
treatment (Fig. 7) suggests CIN plasticity. While other
studies have investigated inhibitory LTD (iLTD) in medium
spiny neurons (MSNs) (Augustin, Chancey, & Lovinger,
2018; Z. Wang et al., 2006), no one has investigated iLTD in
Figure 10: Ethanol inhibits
CIN-mediated DA release.
(A) Light stimulation in
ChAT-ChR2 mice activates
DA release in the striatum that
is inhibited by EtOH (40 mM)
in this representative slice. (B)
Ethanol significantly reduces
CIN-mediated DA release.

accumbal CINs. We confirmed VTA GABA projections to
accumbal CINs by eliciting oIPSCs from VTA GABA
neurons using DIO ChR2 mCherry injected into the VTA of
VGAT-Cre/GAD67-GFP mice and we found robust iLTD of
oIPSCs in accumbal CINs (CIN-iLTD) with the same low
frequency stimulation parameters (LFS; 1 Hz, 240 pulses)

that produce MSN-iLTD (Fig. 11A; One-way ANOVA STATS on oIPSCs). This indicates CINs
undergo GABAergic plasticity similar to MSNs and suggests activity-dependent lowering
inhibition of VTA GABA neurons, a form of inhibitory GABAergic synaptic plasticity in this
pathway (i.e. NAc-VTA). Application of α-Ctx MII significantly reduced CIN-iLTD, suggesting
that α6*-nAChRs mediate CIN-iLTD (Fig. 11B; Two-way ANOVA; Drug: F(1,16) = 5.413,
p=0.0335; LTD: F(1,16)=21.11 , p=0.0003; Interaction: F(1,16) = 7.278 , p=0.0158). To solidify that
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α6*-nAChRs play a key role in CIN-iLTD, we performed the same experiment in mice injected
with α6-shRNA in VGAT-Cre/GAD67-GFP mice and found that CIN-iLTD was also
significantly reduced (Fig. 11B. These findings that both α-Ctx MII and α6- shRNA block CIN-

Figure 11: Role of α6*-nAChRs and atypical GABA receptors in CIN inhibitory plasticity.
(A) Low frequency stimulation (LFS; 1 Hz, 240 pulses) reduced GABAergic oIPSCs in NAc
CINs termed CIN-iLTD. (B) α-Ctx MII or α6- shRNA reduced CIN-iLTD. (C,D). Both NIC
and EtOH reduced CIN-iLTD. (E) Chronic exposure to EtOH reduced CIN-iLTD. (F)
Superfusion of the GABA receptor Rho-1 antagonist also reduced CIN-iLTD.
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iLTD is consistent with the earlier findings that both α-Ctx MII and α6-shRNA block EtOH’s
enhancement of CIN firing rate. Superfusion of 300 nM NIC or 40 mM EtOH also significantly
reduced CIN-iLTD (Fig. 11C,D; NIC: Two-way ANOVA; Drug: F(1,14)=27.17, p=0.0001; LTD:
F(1,14) = 4.9 , p=0.044; Interaction: F(1,14) = 8.218 , p=0.0124; EtOH: Two-way ANOVA; Drug:
F(1,14)=27.17 p = 0.0001; LTD: F(1,14)=4.9 , p = 0.044; Interaction: F(1,14) = 8.218 , p=0.0124).
Consistent with our hypothesis in Aim 3, CIE reduced CIN-iLTD with a trend towards LTP (Fig.
11E; Two-way ANOVA; Drug: F(1,15) = 3.66, p=0.075; LTD: F(1,15)=1.476, p=0.2433 ;
Interaction: F(1,15)=2.399, p=0.1423). Finally, superfusion of the atypical GABA receptor Rho-1
antagonist TPMPA also significantly reduced CIN-iLTD (Fig. 11F; Two-way ANOVA; Drug:
F(1,14)=3.97, p=0.0662; LTD: F(1,14) = 10.48 , p=0.006; Interaction: F(1,14) = 10.41, p=0.0061).
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DISCUSSION
While it is well-known that both NIC and EtOH enhance DA neural activity and basal
DA release in limbic structures, it has become increasingly evident that these effects are not
mediated directly on DA neurons. The purpose of this study was to determine the effects of
EtOH on the GABAergic projection from the VTA to CINs in the NAc, evaluate the role of α6*nAChRs on the GABAergic projection from the VTA to CINs in the NAc, and investigate
plasticity in NAc CINs. Indeed, α6*-nAChR subunit mRNA levels are 16-fold higher than other
nAChR subunits in the VTA (K. Yang et al., 2009) and a highly sensitive target of alcohol (Gao
et al., 2019; Wallner, Hanchar, & Olsen, 2003). We found that EtOH affects the mesolimbic DA
system by acting on the VTA GABAergic projection to accumbal CINs. EtOH reduces
GABAergic transmission, markedly enhances CIN firing rate, and inhibits CIN-mediated DA
release. We also found that α*-nAChRs play a role in EtOH’s effects on this pathway.
My first Aim was to evaluate the role of α6*-nAChRs in mediating EtOH effects on VTA
GABAergic synaptic transmission to CINs in the NAc with the hypothesis that α6*-nAChRs
mediates EtOH effects on VTA GABAergic synaptic inhibition of CINs. The dogma is that α6*nAChRs are only expressed on DA terminals. However, we have previously shown α6*-nAChRs
to be expressed on GABAergic terminals originating from the NAc and projecting to GABA
neurons in the VTA (Steffensen et al., 2017). Bicuculline is the benchmark antagonist for
GABA(A) receptors, but not all ionotropic GABA(A) receptors are sensitive to bicuculline
(Johnston, 2013). Bicuculline (10 µM) did not wipe out oIPSCs in NAc CINs. However,
TPMPA, a very selective antagonist of GABA Rho-1 receptors (Pan, Khalili, Ripps, & Qian,
2005), did block block EtOH’s inhibition of IPSCs. This supports my hypothesis, but suggests a
need for further investigation of the role of atypical GABA receptors on EtOH’s effects on CINs.

28

My second Aim was to evaluate the role of α6*-nAChRs in mediating EtOH effects on
CIN activity and DA release in the NAc with the hypothesis that α6*-nAChRs mediates lowdose EtOH effects on CIN activity. To accomplish this Aim, we used the potent α6-selective
antagonist α-Ctx MII (McIntosh et al., 2004). Indeed, both the pharmacological antagonist α-Ctx
MII and genetic knockdown of α6*-nAChRs in the GABAergic pathway to CINs with α6shRNA blocked EtOH’s marked enhancement of CIN firing rate which supports this hypothesis.
Likewise, TPMPA blocked EtOH’s marked enhancement of CIN firing rate, further suggesting
the need of deeper investigation into the role of atypical GABA receptors. Due to delayed
shipment of α6-shRNA as explained in the limitations below, we were not able to measure EtOH
acute effects on DA release in KO mice injected with α6-shRNA. Had we been able to perform
this experiment, I hypothesize that depleting α6s would affect EtOH’s effects on CIN-mediated
DA release as outlined in my prospectus.
My third Aim was to evaluate plasticity in the VTA GABAergic pathway to CINs, the
role of α6*-nAChRs, and changes in plasticity in EtOH-dependent mice with the hypothesis that
LTD of GABAergic input to CINs would switch to LTP in EtOH-dependent mice. Knockdown
of α6*-nAChRs with α6-shRNA increased CIN baseline firing rate, suggesting cholinergic
dysregulation. EtOH-dependent mice did not exhibit CIN-iLTP as hypothesized. However,
iLTD was blocked. The pharmcological antagonist α-Ctx MII and the genetic knockdown of
α6*-nAChRs with α6-shRNA also blocked CIN-iLTD, demonstrating involvement of α6*nAChRs in CIN-iLTD and α6*-nAChR mesolimbic changes during alcohol addiction. Similarly,
EtOH did not affect CIN firing rate in mice in withdrawal from chronic EtOH, suggesting
tolerance to EtOH. Since TPMPA also blocked CIN-iLTD, further investigation is needed to
establish the role of atypical GABA receptors in mediating the effects of chronic EtOH and
associated CIN plasticity.
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Project Limitations
The COVID-19 pandemic in March combined with the protests associated with the death
of George Floyd in Minnesota resulted in 3-months of delayed shipping of more α6-shRNA from
Co-I Lee at the University of Minnesota. Had we been able to obtain more of the virus as
planned, we would have evaluated the effects of α6*-nAChR knockdown in the VTA
GABAergic pathway to CINs, including CIN-iLTD, in EtOH dependent mice and air-exposed
controls injected with α6-shRNA. A positive COVID-19 case in our lab resulted in the inability
to work in the lab for 2 weeks, further slowing this project down.

Clinical Implications
These findings have significant clinical implications. Alcohol use disorder and tobacco
use disorder, both currently defined in the Diagnostic and Statistical Manual, 5th Edition (DSM5), are serious psychiatric disorders with high medical, psychiatric, and social consequences. To
date, only 3 medications have been approved by the US Food and Drug Administration (FDA) to
treat AUD: disulfiram, naltrexone, and acamprosate, and a number of alternative medications are
now being evaluated for treatment of AUD in human studies including varenicline (Chantix), a
drug historically used to treat TUD. However, these medications have a range of side effects and
a mixed efficacy (Litten, Wilford, Falk, Ryan, & Fertig, 2016). Elucidating a clear molecular
target of EtOH and finding how EtOH changes the reward pathway of the brain on a molecular
level is key to not only directly treat the disorder, but perhaps halt or even reverse dangerous
changes in the brain associated with AUD. Understanding the role of nAChRs in alcohol
addiction will also lead to a better understanding of nicotine addiction and the development of
safer and more effective treatments for TUD and co-occuring TUD and AUD.
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Future Directions
Further investigation is needed to determine the role of atypical GABA receptors in
medicating the effects of acute and chronic EtOH as well as CIN plasticity. Rho-1 is one atypical
GABA receptor, but TPMPA is an antagonist of other atypical GABA receptors like Delta.
Along with further investigating the role of atypical GABA receptors, we plan to investigate the
effects of NIC on this synapse and transition into behavioral studies. Preliminary data (not shown
here) suggests that NIC (300 µM) also enhances CIN firing rate and blocks CIN-iLTD like
EtOH, with the exception that NIC’s enhancement of firing rate plateaus, suggesting
desensitization of nAChRs. This suggests that both NIC and EtOH behave similarly at this
synapse, suggesting that this synapse may be responsible for the stimulatory effects of EtOH. In
our next experiments, we aim to investigate the effect of α-Ctx MII on NIC’s effects on CIN
firing rate and repeat these experiments in general with NIC and compare them to the effects of
EtOH. We also aim to further elucidate the biphasic effects of EtOH. In preliminary studies,
EtOH enhanced optically-evoked, CIN-mediated DA release, but in a biphasic manner with low
doses mildly enhancing and high doses inhibiting release. In this study, we found a marked
enhancement of CIN firing rate at higher doses of EtOH, suggesting a need to further clarify this
biphasic effect.
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